Apellis Pharmaceuticals/ US03753U1060 /
| 2024-05-21 9:59:55 PM | Chg. -0.65 | Volume | Bid- | Ask- | High | Low |
|---|---|---|---|---|---|---|
| 42.59USD | -1.49% | 40,450 Turnover: 1.71 mill. |
-Bid Size: - | -Ask Size: - | 43.17 | 41.64 |
GlobeNewswire
05-16
Investigation Alert: Cummins, Apellis Pharmaceuticals, Inspire Medical, and Applied Digital - Johnso...
GlobeNewswire
05-14
Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facilit...
GlobeNewswire
05-06
Apellis Pharmaceuticals to Host a Fireside Chat at the Bank of America Securities Healthcare Confere...
GlobeNewswire
05-01
Apellis Announces 11 Oral Presentations at the Association for Research in Vision and Ophthalmology ...
GlobeNewswire
04-26
Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by Europe...
GlobeNewswire
04-23
Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financ...
GlobeNewswire
04-04
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
04-01
Apellis Pharmaceuticals to Host a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Confer...
GlobeNewswire
03-19
Investigation Alert: Cummins, Apellis Pharmaceuticals, Inspire Medical, and Applied Digital - Johnso...
GlobeNewswire
03-15
American Kidney Fund Announces 2024 Class of Corporate Members Providing Support in the Fight Agains...
GlobeNewswire
03-11
Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor
GlobeNewswire
03-07
EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights ...
GlobeNewswire
03-06
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
03-05
Investigation Alert Driven Brands Holdings, Apellis Pharmaceuticals, Inspire Medical, and Applied Di...
GlobeNewswire
03-04
EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Offic...
GlobeNewswire
02-27
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
GlobeNewswire
02-20
Apellis Pharmaceuticals to Host Conference Call on February 27, 2024, to Discuss Fourth Quarter and ...
GlobeNewswire
02-06
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
01-26
Apellis Announces Negative CHMP Opinion for Pegcetacoplan for GA in the European Union and Plans to ...
GlobeNewswire
01-16
Investigation Alert Apellis Pharmaceuticals, KeyCorp, ACI Worldwide, and Applied Digital: Johnson Fi...
GlobeNewswire
01-08
Apellis Announces Preliminary Fourth Quarter and Full Year 2023 U.S. Net Product Revenues
